Position Statement: DPP-4 inhibitors (gliptins) in the management of Type 2 Diabetes

Sitagliptin is the first line/preferred cost-effective gliptin. Sitagliptin is first line for all eligible patients/new initiations. Where existing patients are prescribed a different gliptin, and ongoing prescribing of a gliptin is indicated following diabetes review, switch to generic sitagliptin if appropriate.

 Linagliptin is the second line gliptin to be used only after sitagliptin has been tried, or if eGFR <45ml/min/1.73m2